ABOUT BOSTONSIGHT

BostonSight is a nonprofit healthcare organization that advances the treatment of diseased or damaged corneas and dry eye. Our ongoing commitment to research and achieving optimal patient outcomes through innovative scleral lens design, education, and technology have saved the sight of thousands of people around the world.

VISION

A world where no one suffers loss of sight from diseased or damaged corneas and dry eye.

MISSION

To improve quality of life by transforming the understanding, treatment, and care of the ocular surface.

WHAT’S INSIDE

Letter from the President and Board Chair............ 3
Clinicians and Senior Staff ........................................... 5
2022 Giving ............................................................... 6
Education ................................................................. 7
Global Access and Manufacturing ......................... 9
Research .................................................................. 10
Patient Stories .......................................................... 11
2022 Donor Roll ...................................................... 15
2022 Financials ........................................................ 23
It is with great pleasure that we present the 2022 Annual Report for BostonSight. Over the past year, we have continued to make significant progress in delivering on our mission of providing innovative, high-quality treatment, impactful clinical research, eye-opening education, and advanced scleral lens technology to patients around the world.

Since 1992, we have seen the life-changing impact PROSE treatment and scleral lenses provide. Each day we are grateful to share in the joy from patients and their families as pain is diminished and sight is restored. As we have grown, we have been steadfast in keeping the patient at the core of our organization – not only the patients in our Needham Clinic, but also the patients in PROSE Provider Network sites, and BostonSight SCLERAL practitioner offices down the road or halfway around the globe.

Our experience with patients fuels our commitment to playing a significant role in the global adoption of scleral lenses. We continue to search for ways to bring hope to patients who do not yet know about the life-changing treatment of scleral lenses or who are in areas of the world where access to scleral lens technology is limited.

In 2022, we saw significant growth in our reach to patients. In the United States and Canada, we added 74 optometry practices to the BostonSight SCLERAL network, bringing the total to over 400 practices in North America. Our partners in Latin America and India saw major growth in patient access and expanded reach to new countries. To broaden availability around the world, we entered into an agreement with a leading contact lens manufacturer in Europe to manufacture and distribute BostonSight SCLERAL lenses in Spain, Portugal, and Morocco.

We are proud of this growth across the globe and increasing access to scleral lens technology for patients who will benefit. We embrace that improved and expanded access must be supported by complementary efforts to empower new practitioners to be successful through exceptional education and training in the art and science of scleral lens design and treatment.

In 2022 we launched several new initiatives to support the education and professional growth of practitioners, including our first FitAcademy International where we welcomed practitioners from Europe to the Needham Clinic for an immersive clinical education experience.

To complement our ongoing events with optometrists who are most likely to fit and prescribe scleral lenses, Dr. Daniel Brocks, BostonSight’s Chief Medical Officer, began offering a series of lectures to ophthalmology residents at universities around the country. These virtual lectures provide a basic education on PROSE treatment and scleral lenses in the management of ocular surface disease. Ophthalmology residents receive little-to-no training on scleral lenses, and the goal with these lectures is to give emerging clinicians a better understanding of when to recommend specialty lenses to their patients and how to co-manage specialty lens treatments with optometrists.

continued on next page
This year, we welcomed three PROSE Fellows to Needham to complete their training as they joined PROSE Provider Network sites in the United States and Canada. This was exciting for all, as we had to take a several-year break from onsite training due to the pandemic.

We also welcomed our official ambassador, Lensy, a scleral lens character created by Dr. Brocks. Her mission is to help teach pediatric patients about scleral lenses in a child-friendly, accessible way. She has become a plush toy, and her welcoming smile and round scleral lens-shaped body make her a cuddly companion for pediatric patients. She will have a larger presence in 2023.

We expanded our fundraising with a new event – the Falmouth Road Race. Six runners, including BostonSight staff and a PROSE Network Provider, took on the task of running 7 miles along the Cape Cod coast while generating donations for BostonSight. Fundraising is essential to helping ensure any patient who can benefit from scleral lens treatment can do so, regardless of financial status. Fundraising also helps drive our self-funded education and research initiatives.

Finally, we underwent a significant renovation of the Needham Clinic entrance to improve clinical flow, modernize the space, and provide a more comfortable experience for patients.

We thank you for your ongoing support and look forward to another successful year of saving sight together.

With thanks,

Sara Yost, MBA
President and CEO
**CLINICIANS**

**Daniel C. Brocks, MD**  
*Chief Medical Officer*

**Karen G. Carrasquillo, OD, PhD, FAAO, FSLS, FBCLA**  
*Senior Vice President, Clinical and Professional Affairs*

**Alan Kwok, OD, FAAO, FSLS**  
*Director of PROSE Network Clinical Relationships*

**Bita Asghari, OD, FAAO, FSLS**  
*Associate Director of Clinical Education*

**Chirag Patel, OD, FAAO**  
*Associate Director of Innovative Technologies*

**SENIOR STAFF**

**Sara Yost, MBA**  
*President and CEO*

**Cheryl Sadeli, MBA**  
*Chief Financial Officer*

**Laurel Villers**  
*Chief Business Development Officer*

**Manoel Carvalho**  
*Director of Lab Operations*

**Michele Hart**  
*Director of Marketing and Communications*

**Melinda Kimball**  
*Director of Human Resources*

**Darlene Riordan**  
*Director of Clinical Operations*

**Olga Tomashevskaya**  
*Director of Engineering*
Our promise to patients is to provide the best sight-saving care possible. Our promise to practitioners is to empower them to deliver successful patient outcomes.

This year we raised $342,135 thanks to you.

Your gifts save sight by providing education to the public, patient, and professional eye health communities; research and technological innovation that advances the design, manufacturing, and application of PROSE devices and scleral lenses; and financial assistance to patients in need.
Education remains a critical part of our mission. And each year, we find new ways to train and empower eye care practitioners around the world. In 2022, we continued our FitAcademy for Residents retreat, bringing 37 cornea and contact lens residents and fellows from the United States and Canada to the New England College of Optometry (NECO) in Boston for a weekend-long training. The training included lectures from 11 faculty along with experiential learning, where students learned directly from BostonSight optometrists how to fit scleral lenses on patients. Continued partnership with NECO, along with support from the John Henry Family Foundation, Glaukos, and Contamac, help us provide this educational event at little to no cost for the students.

In 2022, we expanded our FitAcademy portfolio of events to add a new program for practicing optometrists abroad. FitAcademy International took place in partnership with OptoAcademy, a leading training academy based in Spain. More than 15 optometrists from Spain joined us in the Needham clinic for a didactic educational component, worked alongside BostonSight’s clinicians to observe patients and treatment modalities, and spent time in the manufacturing lab learning how lenses are made.

Dr. Daniel C. Brocks, BostonSight’s Chief Medical Officer, launched an introductory training for ophthalmology residents. As a practicing ophthalmologist, he recognizes the limited education ophthalmology residents receive on scleral lenses. In these virtual one-hour sessions, he explores the use of PROSE and scleral lenses in the management of ocular surface disease with the intent to raise awareness and help residents prepare for co-management of ocular surface disease cases. He presented to five ophthalmology resident programs including Georgetown-Washington Hospital Center, University of South Carolina,
Dr. Brocks also introduced the world to Lensy, a scleral lens drawing he created to help explain his work to his young children. Lensy is BostonSight’s new ambassador, serving to educate and raise awareness about scleral lenses in a fun and joyful manner. She will help to engage our PROSE sites in media outreach, support pediatric care, and provide future fundraising opportunities. She made her debut at FitAcademy 2022 at NECO, and then worked across the conference circuit, meeting optometrists at the International Congress of Scleral Contacts (ICSC) event in Fort Lauderdale, Florida.

Dr. Alan Kwok coordinates BostonSight’s visiting resident program. Visiting residents spend several days at the Needham Clinic shadowing our PROSE doctors and learning about the latest in ocular surface disease treatment. In 2022, we welcomed residents from Massachusetts College of Pharmacy and Health Sciences (MCPHS), New England College of Optometry (NECO), Veterans Affairs (VA) clinics, and Dorchester House.

We also hosted three new PROSE Fellows treating patients at PROSE Provider Network Sites to the Needham Clinic to complete their PROSE training in person, after a two-year absence from such events. It was a delight to welcome Dr. Brittany Yelle of Precision Cornea Centre Ottawa, Dr. Christina Abuata of Alkek Eye Center at Baylor College of Medicine, and Dr. Britney Kitamata-Wong of the University of California San Francisco.

Rounding out our educational initiatives, BostonSight doctors presented or hosted 31 events, and our webinars had attendees from 21 countries.
Global access to BostonSight SCLERAL technology increased dramatically in 2022. Our partners in Latin America and India, Spectrum International and LV Prasad Eye Institute, saw record growth in BostonSight SCLERAL patients and LV Prasad Eye Institute also saw growth in their PROSE treatments.

In 2022, we continued global expansion by signing a partnership agreement with Conóptica of Spain, a subsidiary of Hecht Kontaktlinsen, a premier vision care company in Germany. Conóptica has been providing gas-permeable lenses, eyecare equipment, and training to eye care practitioners in Spain and beyond since 1963. Under the agreement, Conóptica will manufacture and distribute BostonSight SCLERAL lenses in Spain, Portugal, and Morocco, and may expand to additional European markets in the future.

This partnership brings us one step closer to making sure that everyone who needs a scleral lens, anywhere, can access one.
RESEARCH

In 2022, we continued the growth of our prospective clinical research trials program. Clinical research helps fulfill our ongoing mission to save sight and is an integral part of the work we do. With research, we can make advancements in treatment, helping the eye care community increase utilization of methodologies that improve outcomes for ocular surface disease management.

We worked toward optimizing our study enrollment strategies, completed several prospective studies, and have studies that will continue to be underway in 2023. In addition, we have active interest from Contract Research Organizations, which recognize BostonSight as a successful and prominent research program in the field of ocular surface disease and management.

Research also provides opportunities to collaborate with others in the eye care industry, strengthening professional relationships. Further clinical trial growth is planned for 2023, including multi-site studies.

BostonSight staff published nine peer-reviewed articles or book chapters in 2022, including topics such as “A multi-parameter grading system for optimal fitting of scleral contact lenses,” “Novel patient training technique for the application and removal of scleral lenses,” “Pediatric applications,” and “OSDI outcomes based on patient demographic and wear patterns in PROSE.”
PATIENT STORY

Thank you to Scott K. who submitted his family’s story on our website. Patient stories are incredibly important in helping others better understand the need for and the process and benefit of PROSE treatment.

“During the summer of 1997, our daughter, age 8, had an allergic reaction to Bactrim, for which she was on day 9 of a 10-day regiment. We took her to a children’s hospital in Atlanta, Georgia, where she was diagnosed with Stevens Johnson Syndrome (SJS). It was 10 days of hell for her, my wife, and me. The most severe effects of SJS were with her eyes. Light hypersensitivity, constant pain, and constant corneal ulcers all contributed to her anxiety (and ours). For 18 years, our daughter dealt with the above.

At age 26, our daughter’s eye doctor informed us about the PROSE treatment. We took her to Boston during Thanksgiving week of 2015. The staff were so supportive. The men, women, and children who we met who were being treated all had life-changing stories to tell about their journey to be at Boston. It was truly a miracle!

The very first day, after being fitted with PROSE devices, my daughter was able to go outside, in the daylight, not having to wear two pairs of sunglasses!

From that first day, our lives changed for the better. She had endured 18 years of misery because of her eyes, and just having the ability to be able to view the world through new eyesight was absolutely life changing. We are truly grateful for BostonSight! My daughter has since married. She and her husband have a healthy baby boy! Thank you, BostonSight, for changing our lives and the lives of many that we met on our first journey. We are very grateful!”

“PROSE treatment is a patient-centered model. The patient is at the core of what we do. That means that the practitioners offering PROSE treatment, what is in our hearts and our minds, is the patient. And we will do everything that we can, and then some, to make sure that our patients are successful.”

– Dr. Karen Carrasquillo
PATIENT STORY

Grace Avila is a patient of PROSE Network Provider Dr. Christina Abuata of Alkek Eye Center at Baylor College of Medicine

Grace Avila was having back pain when her physician prescribed a muscle relaxer. Within a few weeks, blisters appeared across her body. Doctors thought she had hand, foot, and mouth disease, a common viral infection in young children that sometimes occurs in adults. Over and over, she was told, “Just let it run its course.” But to Grace, whatever was happening to her body felt like it was eating her alive. She couldn’t eat, walk, or see. When her sister visited, she immediately called 911. Grace had blisters covering her mouth, eyes, throat, torso, and more. “I’d rather be dead than be here,” she told her sister.

A nurse by profession, her sister was convinced Grace had Stevens Johnson Syndrome (SJS), a severe condition that affects the skin, genitals, eyes, and mucous membranes, including the lining of the digestive tract. SJS is caused by an adverse reaction to medication or, sometimes, infection and can cause severe symptoms such as Grace’s that require months to heal, if they heal at all.

Grace’s condition was so debilitating that she spent two weeks in the hospital with her eyes completely covered by bandages and her mouth sealed shut because of blisters. She was kept alive via IV fluids. After two weeks in care, she had surgery, where surgeons placed membranes on her eyes to prevent further scarring. Following her hospital stay and surgery, Grace’s left eye didn’t produce any tears, and it never will again. When she cries, the eye becomes terribly swollen.

Grace was devastated. An avid athlete, she did CrossFit every day and ran marathons. Now, she could barely walk, and she was unable to see.

“I needed one hundred percent help after I got out of the hospital,” Grace says.

“I needed help caring for my children, my sister had to bathe me, I couldn’t work, and then six months later, my mother passed away. It was the worst year of my life. I didn’t want to open my eyes because the pain was so excruciating. I had ointment and drops and drops and drops, but they never really helped.”

continued on next page
Thus, Grace turned her attention to her vision and healing to find the best doctors. She didn’t understand why she couldn’t just get a new cornea. She saw a corneal specialist at Memorial Herman Health in Houston, who referred her to Dr. Stephen Pflugfelder, an ophthalmologist at Baylor College of Medicine. He recommended PROSE.

PROSE is a comprehensive medical treatment that includes cornea specialist ophthalmologists and optometrists who have completed an intensive BostonSight PROSE Clinical Fellowship. During treatment, doctors customize PROSE devices, highly specialized scleral lenses, out of gas-permeable polymers for each patient’s condition and unique eye shape. The devices are filled with preservative-free saline and placed on the sclera, the white part of the eye. The saline is in direct contact with the cornea and provides a constant flow of moisture to the eye.

continued on next page
“The ocular surface is a target of SJS, which causes scarring of the eyelids, conjunctiva, and ducts of the tear glands,” says Dr. Pflugfelder. “This often leaves patients with a severely dry ocular surface that is susceptible to trauma from the scarred eyelids and turned-in eyelashes during blinking. Patients may experience severe eye discomfort and light sensitivity, and, over time, these problems can cause sight-threatening cornea clouding.”

“PROSE is the optimal therapy for this condition because it keeps the cornea moist and shields it from the irregular eyelids and lashes. Patients experience almost immediate relief from their eye discomfort and light sensitivity when the devices are placed on the eye. It can preserve their vision and allow them to return to a normal functional life,” he says.

Together, Dr. Plugfelder and Dr. Christina Abuata, a PROSE Provider, worked with Grace to design a custom prosthetic device for her left eye. She has been wearing a 19mm device on her left eye for the past nine years and recently received a PROSE device for her right eye, too.

“Most SJS patients will need to use artificial tears, ointments, and prescribed medications to feel relief throughout the day,” said Dr. Abuata. “However, this sometimes isn’t enough, and a more aggressive treatment is required. PROSE is an alternative treatment that is indicated for patients with SJS that can help them feel better, see better, and go back to their normal lives.”

Grace says the PROSE devices can be a bit uncomfortable because of her eye condition, but that pain and discomfort are different feelings.

“Without PROSE, I cannot live,” Grace says. “I cannot open my left eye. It burns. It doesn’t produce tears. It’s like day and night when I put my PROSE devices in. I get up at four in the morning to put them in so I can work out.”

“I’d rather be a little uncomfortable to start and not be in pain. It’s an absolute relief when the devices are on.”

It took more than a year for Grace to heal and manage the emotional toll of the disease and her mother’s death.

“It took me a long time to accept what was wrong with me,” she says. “I was a size zero because I couldn’t eat, but slowly, as I healed, I started eating better. I went on retreats, had counseling, and prayed a lot. I had to learn how to cope with losing my mother and my health. I lost me, and I had to find me again.”

She gives thanks to God for the support of her family and her workplace, knowing that not everyone is so fortunate.

“Your health is completely shattered with SJS,” she says. “I didn’t want to live. PROSE changed my whole life. I one hundred percent can open my [left] eye. I have twenty-twenty vision. I can see. I would sell a kidney for this if I didn’t have such good insurance. I want to share my story because it’s unbelievable how much pain you’re in, and then, Bam! No more pain. We need PROSE.”
LIFETIME GIVING

The Lifetime Giving donor roll recognizes donors who have made significant contributions over the life of their giving.

$250,000+

- Bausch + Lomb World Headquarters
- Frank Berry
- John W. Henry Family Foundation
- Bruce and Holly Johnstone
- Thomas Anthony Pappas Charitable Foundation
- Michael and Myra McCoy
- Nehemias Foundation
- Renee Rapaporte
- Kate Weingarten

$100,000 - $249,999

- Anonymous
- Wendy Appel
- The Barbara Epstein Foundation, Inc.
- Harry and Honore Birkenruth
- Henry and Diane Bisgaier
- Blue Cross Blue Shield of Massachusetts Foundation
- Eugene and Irena Bonte
- Boston Eye Associates, P.C.
- The Charles Evans Foundation
- Earmark
- Yuriy Fershter
- Geunyoung Yoon, University of Rochester
- Google
- John Pevarnik Charitable Trust
- Florence Koplow
- Lauren Marino
- Michael Nash
- Robert Remis
- Robert Schaeberle
- Valya Shapiro Esq.
- Enid Starr, Esq.
- Tonna Trust

“One of my favorite things is working with patients on a daily basis and trying to understand what their goals are, what are the things they are missing, and what they want to get back to. And helping them reach those goals through the treatment that we provide them.”

- Dr. Daniel C. Brocks
LIFETIME GIVING

$50,000 - $99,999
Lorne Abony
Helaine Allen
Anonymous
Anonymous
Evelyne Balboni
Bresky Foundation Corporation
Elliot and Nancy Comenitz
Competitive Technologies
Leroy and Jane Crosby
Sumner and Esther Feldberg
Paul Ferri
Gerald Flaxter Charitable Foundation
Howard Gorin
Allan and Anne Greenberg
John and Olga Guttag
Ann Hintlian
Johnson & Johnson
Avinash and Anuja Lele
Joe Martini
Max & Selma Kupferberg Family
Foundation
Michael Moskow
Oculus, Inc.
Larry Plotkin
Michael B. Raizman
Paul Rocca
Howard Stoner
Alan Strassman
Paul Szczygieł
Warren Alpert Foundation
Joe and Susan Zienowicz

$25,000 - $49,999
Amelia Peabody Foundation
Pamela Anderson
Bausch + Lomb
Blue Cross Blue Shield of Massachusetts
Judith Caro
David and Nettie Cohen
Mark Cohen
Dennis and Jillian Corkum
Rachel Dombrowsky
Eastern Bank Charitable Foundation
Gary and Susan Fentin
Jerry and Jane Gnazzo
Stephen Goldenberg
Joseph Hanna
Donnie and Adina Hartman
Jack and Ruth Hirsch
Indo-American Eye Care Society
Deborah S. Jacobs
Joseph C. and Esther Foster Foundation
Shaun and Kathleen Levesque
Roger Marino
Edwin and Barbara Miller
Tom Rosse
Andrew Salk
Alfoncina Sandoval
Hope Smith
Testa, Hurwitz & Thibeault, LLP
The Theodore W. & Evelyn G. Berenson
Charitable Foundation
Dimitrios Voutselas
Peter Wilson
Donald Wright
Yawkey Foundation II
2022 VISIONARY CIRCLE OF HOPE

The Visionary Circle of Hope recognizes donors who have given a gift greater than $1,000 in the giving year.

**$25,000 +**
- Google, Inc.
- John Pevarnik Charitable Trust

**$10,000 - $24,999**
- Henry and Diane Bisgaier
- Eugene and Irena Bonte
- The Barbara Epstein Foundation, Inc.
- Paul Ferri

**$5,000 - $9,999**
- Pamela Anderson
- Allan and Anne Greenberg
- Johnson & Johnson
- Bruce and Holly Johnstone
- Joe Martini
- Michael Nash
- Michael B. Raizman
- Julie Rutenberg
- Edward Tanzman and Ellen Partridge

**$1,000 - $4,999**
- Thomas Arnold
- Thelma Axberg
- Marci Azbell
- Bank of America
- Harry Branning
- The Bresler Foundation
- Alicia and Glen Bunnell
- Steve Chang
- J. Stephen Collins
- Leroy and Jane Crosby
- Michael Daily
- Gerard De Gunzburg
- Michael Dominguez
- Mary Dunbrack
- Eastern Bank Charitable Foundation
- Gary and Susan Fentin
- Glaukos Corporation
- Karen Grossman
- Judith Gurewich
- Gene Guselli
- Evan Haberman
- Donniel and Adina Hartman
- Jon Inwood
- Scott and Laura Keesee
- Michael P. and Vicki Link
- Anna K. Mergen
- Peter and Robin Muise Fund
- Roberta Neal
- Novartis
- Carmen Paradis
- Providence Equity Partners, LLC
- Howard Purcell
- QCD
- J. Royce
- Delia Sattin
- John Shesky
- George Tonna
- Steven Weber
- Roger Wellington
- Sara and Jason Yost
2022 DONORS

$500-$999
AmazonSmile Foundation
Glenn Barest
Gary Bedrosian
Alyson Berliner
Marie Britt
Charles and Sarah Shoaf Cabot
Jean and John Conners
Vincent Fratello
Christopher Garrison
Elise Hauenstein
Douglas and Edythe Jablonsky
Jay Kelly
Andrea Knight
Avinash and Anuja Lele
Eleanore Moran
Charles Rehn
Ron Remy
David Rosenbloom
Laurel and Paul Villers

$499 and below
Rao Addanki
Aya Adichi
Deanne Aguirre
Virginia Alden
Brayden Alexander
Marcia Allar
American Online Giving Foundation
AmFam
Anonymous
Steven Appel
Wayne Arruda
Norman and Monique Avey
Bonnie Bader
Aaron Baumgarten
Mary Bazinet
Michael Bedrin
Margie Benefico
Benny and Bella Benjamin
Edward Bennett
John Berberich
Sandra Berinato
Steven Berliner
Jonathan Biegen
Harry and Honore Birkenruth
Kayte Bleakney
Glenn Bochner
Steven Bogatz
Rosemary Boling
James Bond
Andrea Bonte Arcuri
Mike Borgia
Shannon Bourg
Robert Bower
Joann Bowman
Helen Bragdon
Peter G. and Sally Brassard
2022 DONORS

$499 and below

Daniel Breen
Jack and Nancy Brennan
Maurice Brown
Amparo Brown
Jeremy Bunting
Marcia Burch
Nancy Busby
Patricia Byrne
Pamela Cacace-Crepeau
Ellen Caliendo
Barbara Calkins
Margaret Cannell
James Cannon
Abby Caplin
Mark Carmon
Lynn Carter
Steven and Kathleen Case
Carroll and Raymond C. Charette
Arthur and Carole Chen
Mary Conde
Ross Connelly
Paul K. Connolly
Anne Connors
Hajnalka Coon
Tain Corless
Susan Costello
Carol and Timothy Reed Counihan
Marc and Lynne Craft
Stephanie Craig
Helene Curley
Brad Currier
Kimberly Cyr
Maureen DeCenzo
Jessica DeCenzo
John Delude
Jeffrey Dibona

$499 and below

Miche Donjacour
Richard and Joan Donnelly
Sean and Sarah Dorfman
Michael Dorsett
Tammy Downes
David Driscoll
Michael Driscoll
Roberta Drury
Daniel Durack
Julie Echols
Bernard and Lois Edinberg
Greta Ehrstein
Aileen Elizabeth
Lewis and Carol Epstein
Norman and Mary Jo Everett
Joe and Maureen Fazio
Morgan Feenstra
Naomi Fernandes-Pucillo
Bill Finklea
Davina Finn
Mark and Lesley Finn
Peter Fitzrandolph
Jeanette Flores
Renard and Mary Francois
Bernard Fried
Anthony Fucillo
Todd Gaddy
Laurie Garin
Kim Gavagan
Judy Geleerd
Derek George
Donna Gilbert
Jacqueline Gilbert
Adam Gill
Give Lively Foundation
2022 DONORS

$499 and below

Global Foundries
Juan and Christine Gonzales
Rhonna Goodman
Peter Gordenstein
Gary Green
Peter Greven
Shirley Guidoboni
Helen Harney
Michele Hart
Kenneth Hengeli
Blake Henry
Kathleen Hill
Mari Hirsh
Judith Hochstadt
Robert Holland
Diane Horan
Lois Horowitz
Marcus Hughes
Karen Hunt
Barry Hyman
Jeannette Iles
Leonard and Barbara Insalaco
Deborah S. Jacobs
Frances Jeffries
Klavs Jensen
Peter Jones
Jesse Kaminski
Lyn Kaminski
Adolph Karchmer
Robert and Geraldine Kastner
Joel Katz
Dwayne and Deborah Kepner
Sonia Ketkar
Melinda Kimball
Michael King
Barry Kirshner

$499 and below

Jill and Jeff Kleeman
Joni Klippert Sarranfian
Gary Knaak
Ellen Knizeski
Ilene Knopping
Ilana Kraus
Karen Krugler
Jason Kurant
John Lanacone
Ann Lange
Linda Large
Theresa Laster
Mastor Lau
Judi Lazo
Keng Lee
Michelle Leigh
Robyn Lemnah
Paul Levine
Sharon Levitan
Martin and Sandra Levy
Martyn Lewis
Joe Lifland
Jack Lindberg
Viola Lundberg
James MacGregor
Mark Maciolek
Sarah MacQuarrie
Michele Malgieri
Sandra Mann
Raymond and Mary Marble
Marguerite Marsh
Joseph and Patricia Marzetti
Matthew and Margarethe Mashikian
Daniel and Sheila Massarelli
MasterCard
Jack Mayer
2022 DONORS

$499 and below
Mark and Sandra Mazur
Karen McAnern
Nancy Mercado
Robert Metafora
Richard Metcalfe
Cris Mikkelsen
Kalvin and Jan Milan
Nancy Miller
Thomas Mills
McKinley Mitchell
Pamela Morgan
Alireza Nazeri
Diane Norton
Jayme Nozzi
Richard and Patricia O’Brien
Eli Okrant
Shannon O’Neill
Barbara Oravec
Wanda Ortiz
John Owen
Elaine Pagliaroli Provenzano
Gina Parkinson
Nancy Paull Nida
Paul Pavljuk
Beverly Peiser
Jennifer Perkins
William Peterson
Rebecca Petris
Teri Piatt
Ellen Pichey
John Pieroni
Tamela Pink
Paul Piselli
Joan Porco
Daniela Prodanovic
Roisin Pucillo

$499 and below
Christopher Quental
Linda Racine
Geraldine Radzanowski
Noel Ramos
Andrew and Patricia Rebich
Anne Redman-Lyon
Regeneron Pharmaceuticals, Inc.
Moira Riley
Eunice Roberts
Sherri Rockower
Shawn Roman
Leonard Rosenthal
Barbara Rostosky
Jacqueline Royce
James Ruby
John Rumpakis
T. Russo
Nicholla Sacks
Shahzad Saleem
Neal Schull
Clifford Scott
Maureen Seith
Laura Senft
Ruchika Sethi
Robert Seyler
Sue Sharer
John Shea
Donna Sherman
Peggy Sisselman
Amanda Sisselman-Borgia
Michael Slobodkin
Stephan Smith
Darlene Smolak
Rosalind Spigel
Tara Stepanian
Robert Strom
2022 DONORS

$499 and below
Dennis Strusa
William Sullivan
Patricia Szymkiewicz
Chelsea Szymkiewicz
Matthew Teague
Ginny Terry
Alfred Thoman
David Ting
Bill Tolles
Emily Tourtillotte
Maureen Trusky
Ryan Tucker
Amy Turowski
Tatleen Vassell
Jeff Venuti
Lura Vernon
Todd Vernon
Jean Vnenchak
Dorothy Waldron

$499 and below
Emily Ward
Jonathan Weber
Irwin Weiss
Ma'lis Wendt
Sara Wenger
Marcia Wiker
Norman Wilikofsky
Lorraine Willett
James Willis
Manira Wilson-Bassett
Olin Wood
Barbara Wood
William Wright
Daniel Wywoda
Craig Yarnell
Janice Yost
Maria Zanfini
Nancy Zina

Thank You
# 2022 FINANCIALS

Operating revenue: $8,039M
Operating expenses: $8,057M

## INCOME AND EXPENSES ($ in 000's)

<table>
<thead>
<tr>
<th>INCOME</th>
<th>12/31/2022</th>
<th>12/31/2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Network clinic revenue</td>
<td>$4,143</td>
<td>$3,640</td>
</tr>
<tr>
<td>Patient services</td>
<td>$3,326</td>
<td>$3,086</td>
</tr>
<tr>
<td>Contributions and grants</td>
<td>$352</td>
<td>$1,363</td>
</tr>
<tr>
<td>In-kind and other</td>
<td>$217</td>
<td>$235</td>
</tr>
<tr>
<td><strong>Total Income</strong></td>
<td><strong>$8,039</strong></td>
<td><strong>$8,324</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EXPENSES</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Operating, research, education</td>
<td>$6,786</td>
<td>$6,140</td>
</tr>
<tr>
<td>and teaching</td>
<td></td>
<td></td>
</tr>
<tr>
<td>General and administrative</td>
<td>$1,203</td>
<td>$1,148</td>
</tr>
<tr>
<td>Fundraising</td>
<td>$68</td>
<td>$81</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>$8,057</strong></td>
<td><strong>$7,368</strong></td>
</tr>
<tr>
<td><strong>Net Income</strong></td>
<td><strong>$ (19)</strong></td>
<td><strong>$ 956</strong></td>
</tr>
</tbody>
</table>
# 2022 Financials

## Balance Sheet ($ in 000's)

### Assets

<table>
<thead>
<tr>
<th>Item</th>
<th>12/31/2022</th>
<th>12/31/2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$2,876</td>
<td>$2,788</td>
</tr>
<tr>
<td>Current portion of restricted cash</td>
<td>26</td>
<td>62</td>
</tr>
<tr>
<td>Accounts Receivable - patients</td>
<td>892</td>
<td>639</td>
</tr>
<tr>
<td>Accounts Receivable - network clinics</td>
<td>644</td>
<td>754</td>
</tr>
<tr>
<td>Grants and other receivables</td>
<td>60</td>
<td>90</td>
</tr>
<tr>
<td>Inventory</td>
<td>302</td>
<td>288</td>
</tr>
<tr>
<td>Prepaid expenses and other</td>
<td>152</td>
<td>77</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td><strong>$4,951</strong></td>
<td><strong>$4,697</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other assets</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Right-of-use assets - Operating</td>
<td>2,837</td>
<td></td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>1,343</td>
<td>1,409</td>
</tr>
<tr>
<td>Restricted cash</td>
<td>185</td>
<td>185</td>
</tr>
<tr>
<td>Deposits</td>
<td>33</td>
<td>33</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$9,349</strong></td>
<td><strong>$6,324</strong></td>
</tr>
</tbody>
</table>

### Liabilities and Net Assets

#### Current Liabilities:

<table>
<thead>
<tr>
<th>Item</th>
<th>12/31/2022</th>
<th>12/31/2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$797</td>
<td>$812</td>
</tr>
<tr>
<td>Current portion of note payable</td>
<td>101</td>
<td>95</td>
</tr>
<tr>
<td>Current portion of operating lease liabilities</td>
<td>451</td>
<td>-</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>737</td>
<td>604</td>
</tr>
<tr>
<td><strong>Total current liabilities:</strong></td>
<td>$2,086</td>
<td>$1,512</td>
</tr>
</tbody>
</table>

| Operating lease liabilities, net of current portion                  | 2,566      | -          |

| Note Payable, net of current portion                                | $74        | $172       |
| **Total liabilities:**                                              | **4,727**  | **1,683**  |

#### Net Assets:

| Without donor restrictions                                          | $4,441     | $4,393     |
| With donor restrictions                                             | 210        | 247        |
| **Total net assets:**                                               | **$4,622** | **$4,641** |

| **Total liabilities and net assets:**                               | **$9,349** | **$6,324** |
BostonSight®